mRNA Profiling Reveals Determinants of Trastuzumab Efficiency in HER2-Positive Breast Cancer

Intrinsic and acquired resistance to the monoclonal antibody drug trastuzumab is a major problem in the treatment of HER2-positive breast cancer. A deeper understanding of the underlying mechanisms could help to develop new agents. Our intention was to detect genes and single nucleotide polymorphisms (SNPs) affecting trastuzumab efficiency in cell culture. Three HER2-positive breast cancer cell lines with different resistance phenotypes were analyzed. We chose BT474 as model of trastuzumab sensitivity, HCC1954 as model of intrinsic resistance, and BTR50, derived from BT474, as model of acquired resistance. Based on RNA-Seq data, we performed differential expression analyses on these cell lines with and without trastuzumab treatment. Differentially expressed genes between the resistant cell lines and BT474 are expected to contribute to resistance. Differentially expressed genes between untreated and trastuzumab treated BT474 are expected to contribute to drug efficacy. To exclude false positives from the candidate gene set, we removed genes that were also differentially expressed between untreated and trastuzumab treated BTR50. We further searched for SNPs in the untreated cell lines which could contribute to trastuzumab resistance. The analysis resulted in 54 differentially expressed candidate genes that might be connected to trastuzumab efficiency. 90% of 40 selected candidates were validated by RT-qPCR. ALPP, CALCOCO1, CAV1, CYP1A2 and IGFBP3 were significantly higher expressed in the trastuzumab treated than in the untreated BT474 cell line. GDF15, IL8, LCN2, PTGS2 and 20 other genes were significantly higher expressed in HCC1954 than in BT474, while NCAM2, COLEC12, AFF3, TFF3, NRCAM, GREB1 and TFF1 were significantly lower expressed. Additionally, we inferred SNPs in HCC1954 for CAV1, PTGS2, IL8 and IGFBP3. The latter also had a variation in BTR50. 20% of the validated subset have already been mentioned in literature. For half of them we called and analyzed SNPs. These results contribute to a better understanding of trastuzumab action and resistance mechanisms.

[1]  King-Jen Chang,et al.  CTGF enhances the motility of breast cancer cells via an integrin-αvβ3–ERK1/2-dependent S100A4-upregulated pathway , 2007, Journal of Cell Science.

[2]  Pui-Yan Kwok,et al.  Detection of single nucleotide polymorphisms. , 2003, Current issues in molecular biology.

[3]  G. Basu,et al.  Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. , 2004, Molecular cancer research : MCR.

[4]  Giu-Cheng Hsu,et al.  Genetic variation in the genome-wide predicted estrogen response element-related sequences is associated with breast cancer development , 2011, Breast Cancer Research.

[5]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[6]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[7]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[8]  G. Yousef,et al.  Kallikrein gene downregulation in breast cancer , 2004, British Journal of Cancer.

[9]  Wei Wang,et al.  Methylation of the Claudin 1 Promoter Is Associated with Loss of Expression in Estrogen Receptor Positive Breast Cancer , 2013, PloS one.

[10]  Monilola A. Olayioye,et al.  The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.

[11]  Keda Yu,et al.  No association between a progesterone receptor gene promoter polymorphism (+331G>A) and breast cancer risk in Caucasian women: evidence from a literature-based meta-analysis , 2010, Breast Cancer Research and Treatment.

[12]  D. Baird,et al.  IGF-I and IGFBP-3 Polymorphisms in Relation to Circulating Levels among African American and Caucasian Women , 2009, Cancer Epidemiology Biomarkers & Prevention.

[13]  M. Merville,et al.  Regulation of HER-2 oncogene expression by cyclooxygenase-2 and prostaglandin E2 , 2004, Oncogene.

[14]  B. Qian,et al.  Genotypes and phenotypes of IGF-I and IGFBP-3 in breast tumors among Chinese women , 2011, Breast Cancer Research and Treatment.

[15]  M. Pike,et al.  IGF-1, IGFBP-1, and IGFBP-3 Polymorphisms Predict Circulating IGF Levels but Not Breast Cancer Risk: Findings from the Breast and Prostate Cancer Cohort Consortium (BPC3) , 2008, PloS one.

[16]  P. Sismondi,et al.  Human kallikrein gene 5 (KLK5) expression by quantitative PCR: an independent indicator of poor prognosis in breast cancer. , 2002, Clinical chemistry.

[17]  M. Gill,et al.  Development of Strategies for SNP Detection in RNA-Seq Data: Application to Lymphoblastoid Cell Lines and Evaluation Using 1000 Genomes Data , 2013, PloS one.

[18]  L. Gianni.  The Future of Targeted Therapy: Combining Novel Agents , 2002, Oncology.

[19]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[20]  M. Duffy,et al.  Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib , 2010, Molecular Cancer Therapeutics.

[21]  G. Colditz,et al.  Genetic variation and circulating levels of IGF‐I and IGFBP‐3 in relation to risk of proliferative benign breast disease , 2010, International journal of cancer.

[22]  G Rauch,et al.  Outcome analysis of patients with primary breast cancer initially treated at a certified academic breast unit. , 2012, Breast.

[23]  K. Dahlman-Wright,et al.  Microarray analysis of altered gene expression in ERβ-overexpressing HEK293 cells , 2009, Endocrine.

[24]  Kevin M. Bradley,et al.  Heritable Variation of ERBB2 and Breast Cancer Risk , 2009, Cancer Epidemiology Biomarkers & Prevention.

[25]  Wen-Huan Xu,et al.  Current evidence on the relationship between polymorphisms in the COX-2 gene and breast cancer risk: a meta-analysis , 2010, Breast Cancer Research and Treatment.

[26]  J. Harrow,et al.  GENCODE: producing a reference annotation for ENCODE , 2006, Genome Biology.

[27]  M. Sliwkowski,et al.  Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. , 2001, Gastroenterology.

[28]  Carlos L. Arteaga,et al.  Treatment of HER2-positive breast cancer: current status and future perspectives , 2012, Nature Reviews Clinical Oncology.

[29]  F. May,et al.  TFF3 is a normal breast epithelial protein and is associated with differentiated phenotype in early breast cancer but predisposes to invasion and metastasis in advanced disease. , 2012, The American journal of pathology.

[30]  A. Wolff,et al.  Treatment of HER2-positive breast cancer. , 2014, Breast.

[31]  D. Easton,et al.  Common Polymorphisms in the Prostaglandin Pathway Genes and Their Association with Breast Cancer Susceptibility and Survival , 2009, Clinical Cancer Research.

[32]  L. Morrison,et al.  Effects of ERBB2 amplicon size and genomic alterations of chromosomes 1, 3, and 10 on patient response to trastuzumab in metastatic breast cancer , 2007, Genes, chromosomes & cancer.

[33]  F. Stanczyk,et al.  Selective Loss of AKR1C1 and AKR1C2 in Breast Cancer and Their Potential Effect on Progesterone Signaling , 2004, Cancer Research.

[34]  W. Fishman.  Clinical and biological significance of an isozyme tumor marker--PLAP. , 1987, Clinical biochemistry.

[35]  M. Lacroix,et al.  Significance, detection and markers of disseminated breast cancer cells. , 2006, Endocrine-related cancer.

[36]  M. Mandal,et al.  Regulation of Cyclooxygenase-2 pathway by HER2 receptor , 1999, Oncogene.

[37]  Deborah A. Brown,et al.  Caveolin-1 Induces Formation of Membrane Tubules That Sense Actomyosin Tension and Are Inhibited by Polymerase I and Transcript Release Factor/Cavin-1 , 2010, Molecular biology of the cell.

[38]  J. Isola,et al.  Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. , 2002, Cancer research.

[39]  K. Subbaramaiah,et al.  Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. , 2001, Endocrine-related cancer.

[40]  C. Schmidt,et al.  Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs , 2012, Oncogenesis.

[41]  J. Palmgren,et al.  Comprehensive analysis of the ATM, CHEK2 and ERBB2 genes in relation to breast tumour characteristics and survival: a population-based case-control and follow-up study , 2006, Breast Cancer Research.

[42]  M. DePristo,et al.  A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.

[43]  Y. Lu,et al.  Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). , 2001, Journal of the National Cancer Institute.

[44]  King-Jen Chang,et al.  CTGF enhances the motility of breast cancer cells via an integrin-alphavbeta3-ERK1/2-dependent S100A4-upregulated pathway. , 2007, Journal of cell science.

[45]  M. Wicha,et al.  Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. , 2012, Molecular cell.

[46]  Elspeth A. Bruford,et al.  Genenames.org: the HGNC resources in 2013 , 2012, Nucleic Acids Res..

[47]  M. Zanetti,et al.  Activation of the unfolded protein response bypasses trastuzumab-mediated inhibition of the PI-3K pathway. , 2013, Cancer letters.

[48]  S. Pavanello,et al.  Role of CYP1A2 polymorphisms in breast cancer risk in women. , 2013, Molecular medicine reports.

[49]  A. Schönthal,et al.  Enhanced killing of chemo-resistant breast cancer cells via controlled aggravation of ER stress. , 2009, Cancer letters.

[50]  D. Salomon,et al.  Identification of Caveolin-1 as a Potential Causative Factor in the Generation of Trastuzumab Resistance in Breast Cancer Cells , 2013, Journal of Cancer.

[51]  R. Roskoski.  The ErbB/HER family of protein-tyrosine kinases and cancer. , 2014, Pharmacological research.

[52]  E. Birney,et al.  Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt , 2009, Nature Protocols.

[53]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[54]  R. Nahta,et al.  Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells. , 2011, Biochemical pharmacology.

[55]  J. Baselga,et al.  Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort , 2010, The Lancet.

[56]  Ying-Chu Lee,et al.  International Journal of Biological Sciences , 2011 .

[57]  Tatiana A. Tatusova,et al.  Entrez Gene: gene-centered information at NCBI , 2004, Nucleic Acids Res..

[58]  F. Bertucci,et al.  Protein Profiling of Human Breast Tumor Cells Identifies Novel Biomarkers Associated with Molecular Subtypes*S , 2008, Molecular & Cellular Proteomics.

[59]  I. Ellis,et al.  Expression of luminal and basal cytokeratins in human breast carcinoma , 2004, The Journal of pathology.

[60]  J. Park,et al.  TNF superfamily gene polymorphism as prognostic factor in early breast cancer , 2010, Journal of Cancer Research and Clinical Oncology.

[61]  K. Mehta,et al.  Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancer , 2013, Breast Cancer Research.

[62]  R. Tibshirani,et al.  Copyright © American Society for Investigative Pathology Short Communication Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome , 2022 .

[63]  Travis S. Hughes,et al.  Ligand-binding dynamics rewire cellular signaling via Estrogen Receptor-α , 2013, Nature chemical biology.

[64]  A. Brookes.  The essence of SNPs. , 1999, Gene.

[65]  M. Hung,et al.  Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. , 2004, Cancer cell.

[66]  Yi Shen,et al.  Trastuzumab Regulates IGFBP-2 and IGFBP-3 to Mediate Growth Inhibition: Implications for the Development of Predictive Biomarkers for Trastuzumab Resistance , 2011, Molecular Cancer Therapeutics.

[67]  K. Sirotkin,et al.  dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation. , 1999, Genome research.

[68]  B. Henderson,et al.  Genetic determinants of circulating insulin-like growth factor (IGF)-I, IGF binding protein (BP)-1, and IGFBP-3 levels in a multiethnic population. , 2007, The Journal of clinical endocrinology and metabolism.

[69]  S. Fuqua,et al.  Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression , 2012, Breast Cancer Research.

[70]  B. Leyland-Jones,et al.  Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo. , 2006, Cancer research.

[71]  J. Buring,et al.  A polymorphism in the 3' untranslated region of the gene encoding prostaglandin endoperoxide synthase 2 is not associated with an increase in breast cancer risk: a nested case-control study , 2007, Breast Cancer Research.

[72]  S. Koifman,et al.  Polymorphisms in cycloxygenase-2 gene and breast cancer prognosis: association between PTGS2 haplotypes and histopathological features , 2012, Breast Cancer Research and Treatment.

[73]  M. Dowsett,et al.  EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy , 2010, British Journal of Cancer.

[74]  D. Dixon,et al.  A common single-nucleotide polymorphism in cyclooxygenase-2 disrupts microRNA-mediated regulation , 2012, Oncogene.

[75]  T. Burki.  Adjuvant treatment for HER2-positive breast cancer. , 2015, The Lancet. Oncology.

[76]  F. Montemurro,et al.  Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[77]  C. Hudis,et al.  Phase II Study of Celecoxib and Trastuzumab in Metastatic Breast Cancer Patients Who Have Progressed after Prior Trastuzumab-Based Treatments , 2004, Clinical Cancer Research.

[78]  Zhen Liu,et al.  LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway , 2014, Oncotarget.

[79]  R. Tavares,et al.  Claudin Expression in High Grade Invasive Ductal Carcinoma of the Breast: Correlation with the Molecular Subtype , 2012, Modern Pathology.

[80]  E. Schuuring,et al.  MYEOV: A candidate gene for DNA amplification events occurring centromeric to CCND1 in breast cancer , 2002, International journal of cancer.

[81]  Anton Belousov,et al.  Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study , 2014, Clinical Cancer Research.

[82]  Jeong-Seok Nam,et al.  Dysadherin expression promotes the motility and survival of human breast cancer cells by AKT activation , 2012, Cancer science.

[83]  Daniel R. Zerbino,et al.  Ensembl 2014 , 2013, Nucleic Acids Res..

[84]  M. Baggiolini,et al.  Interleukin‐8, a chemotactic and inflammatory cytokine , 1992, FEBS letters.

[85]  J. Foekens,et al.  Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance , 2002, British Journal of Cancer.

[86]  C. Gomez-Fernandez,et al.  GREB1 Functions as a Growth Promoter and Is Modulated by IL6/STAT3 in Breast Cancer , 2012, PloS one.

[87]  A. Hill,et al.  Growth factor receptor/steroid receptor cross talk in trastuzumab-treated breast cancer , 2014, Oncogene.

[88]  U. Langsenlehner,et al.  Association of interleukin-10 gene variation with breast cancer prognosis , 2010, Breast Cancer Research and Treatment.

[89]  Kevin M. Bradley,et al.  Heritable Variation of ERBB 2 and Breast Cancer Risk , 2009 .

[90]  I. Gray,et al.  Single nucleotide polymorphisms as tools in human genetics. , 2000, Human molecular genetics.

[91]  P. Thompson,et al.  t10c12 Conjugated Linoleic Acid Suppresses HER2 Protein and Enhances Apoptosis in SKBr3 Breast Cancer Cells: Possible Role of COX2 , 2009, PloS one.

[92]  Xuexi Yang,et al.  Mutational analysis of key EGFR pathway genes in Chinese breast cancer patients. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[93]  W. Gerald,et al.  An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen , 2006, Oncogene.

[94]  G. Colditz,et al.  Common genetic variation in IGF1, IGFBP-1, and IGFBP-3 in relation to mammographic density: a cross-sectional study , 2007, Breast Cancer Research.

[95]  Wei Zhu,et al.  −765G>C and 8473T>C polymorphisms of COX-2 and cancer risk: a meta-analysis based on 33 case–control studies , 2009, Molecular Biology Reports.

[96]  Alison M Dunning,et al.  Common ERBB2 polymorphisms and risk of breast cancer in a white British population: a case–control study , 2005, Breast Cancer Research.

[97]  Daniel Rios,et al.  Bioinformatics Applications Note Databases and Ontologies Deriving the Consequences of Genomic Variants with the Ensembl Api and Snp Effect Predictor , 2022 .

[98]  Paul Theodor Pyl,et al.  HTSeq—a Python framework to work with high-throughput sequencing data , 2014, bioRxiv.

[99]  T. Mukohara,et al.  Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[100]  W. Huber,et al.  which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. MAnorm: a robust model for quantitative comparison of ChIP-Seq data sets , 2011 .

[101]  Byong Hoon Yoo,et al.  Progesterone-Inducible Cytokeratin 5-Positive Cells in Luminal Breast Cancer Exhibit Progenitor Properties , 2013, Hormones and Cancer.